Arrowhead Pharmaceuticals, Inc. - Common Stock (NQ:ARWR)

Arrowhead Pharmaceuticals (NASDAQ:ARWR) Rallies as REDEMPLO Launch and Plozasiran Fast Review Offset Earnings Miss ↗

Performance

52-Week Range 50.6% below 52-week high

47.18

37.0652W Low 95.4952W High

1 Week 19.6% below 1-week high

46.451W Low 58.711W High

Arrowhead Pharmaceuticals, Inc. - Common Stock (ARWR) traded between $37.06 and $95.49 over the past 52 weeks and last traded at $47.18, 50.6% below its 52-week high. Over the past week it ranged between $46.45 and $58.71.

Past 12 Months

-18.9%

-18.8%

-44.9%

-40.8%

-30.4%

+13.9%

1W -$10.98

1M -$10.95

3M -$38.41

6M -$32.51

YTD -$20.61

1Y +$5.76

ARWR was +13.9% over the past year, -40.8% over six months, -30.4% year to date, -18.9% in the last week.

12 Months vs Market

ARWR

+13.9%

DIA

+7.9%

SPY

+9.7%

QQQ

+8.5%

IWM

+13.3%

Over the past 12 months ARWR returned +13.9% versus DIA (Dow) +7.9%, SPY (S&P 500) +9.7%, QQQ (Nasdaq 100) +8.5% and IWM (Russell 2000) +13.3%.

Volume & Liquidity 0.66× 3-mo avg

Today 1,238,511 3-mo avg 1.9M

3.3M

2.0M

1.9M

2.0M

YTD

2.3M

ARWR most recently traded 1,238,511 shares against a 3-month average daily volume of 1.9M.

More News

November 12, 2026

Via Chartmill

Arrowhead Pharmaceuticals Reports 2026 Fiscal Year-End Results

November 12, 2026

Arrowhead Pharmaceuticals (NASDAQ:ARWR) Flashes Bull Flag Breakout Setup with Top-Tier Technical Strength ↗

August 26, 2026

Via Chartmill

Arrowhead Pharmaceuticals to Participate in Upcoming Investor Conferences

November 09, 2026

Arrowhead Pharmaceuticals Presents Plozasiran Data Highlighting Sustained Triglyceride Reductions and Reduced Acute Pancreatitis Rates

November 07, 2026

Arrowhead Pharmaceuticals Refinances Existing Credit Facility, Lowering Borrowing Costs and Extending Maturity

November 04, 2026

Arrowhead Pharmaceuticals to Webcast 2026 Fiscal Year-End Results

November 03, 2026

Arrowhead Pharmaceuticals to Present Important Clinical Data at the American Heart Association Scientific Sessions 2026

November 02, 2026

Adults Living with Familial Chylomicronaemia Syndrome (FCS) in England and Wales Have REDEMPLO® (Plozasiran) as a New Treatment Option to Reduce Triglycerides

October 27, 2026

Arrowhead Pharmaceuticals Reports Up to 73% CSF Tau Reduction in Early ARO-MAPT Study ↗

October 14, 2026

Arrowhead Pharmaceuticals Announces ARO-MAPT Interim Phase 1/2a Clinical Data Demonstrating Deep and Durable Tau Reductions in Healthy Volunteers

October 14, 2026

Arrowhead Pharmaceuticals Granted Entry in the FDA STAR Pilot Program for Plozasiran in Severe Hypertriglyceridemia

October 07, 2026

Arrowhead Pharmaceuticals to Host a Webinar with Interim Clinical Data from a Phase 1/2a Study of ARO-MAPT for the Treatment of Alzheimer’s Disease and Other Tauopathies

September 29, 2026

Arrowhead Pharmaceuticals Spotlights Dual-Target RNAi Data, Plozasiran Launch Progress ↗

September 18, 2026

Arrowhead Pharmaceuticals Eyes SHTG Filing as RNAi Pipeline Expands ↗

September 18, 2026

Arrowhead Pharmaceuticals Announces Interim Topline Clinical Data for the First Dual-Functional RNAi Therapeutic for the Treatment of Mixed Hyperlipidemia

September 15, 2026

Arrowhead Pharmaceuticals Director Sells 11,600 Shares for $1 Million ↗

September 06, 2026

Via The Motley Fool

Arrowhead Pharmaceuticals to Participate in Upcoming September 2026 Investor Conferences

September 03, 2026

Arrowhead’s Plozasiran Cuts Triglycerides, Pancreatitis Risk in Phase 3 Trials ↗

August 31, 2026

Arrowhead Pharmaceuticals Presents Phase 3 SHASTA-3 and SHASTA-4 Data Demonstrating Plozasiran Reduced Acute Pancreatitis Events in Patients with Severe Hypertriglyceridemia

August 30, 2026

Arrowhead Pharmaceuticals to Present New Clinical Data at the European Society of Cardiology Congress

August 24, 2026

People Living with Familial Chylomicronaemia Syndrome (FCS) in Germany Have Access to REDEMPLO® (plozasiran) as a New Treatment Option to Reduce Triglycerides

August 17, 2026